Effect of Acetazolamide on Choroidal Morphology in Central Serous Chorioretinopathy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We sought to elucidate the influence of acetazolamide on choroidal structure changes during thetreatment of central serous chorioretinopathy (CSC). Methods: This was a retrospective study of 45 eyes from 45 patients with acute CSC who were divided into anacetazolamide group (group 1, n = 20) and an observation group (group 2, n = 25). The main outcome measureswere the changes in best-corrected visual acuity, subretinal fluid (SRF) height, subfoveal choroidal thickness(SFCT), and choroidal vascularity index (CVI) at one week, one month, two months, and three months,respectively. Results: Although statistical significance was not reached, best-corrected visual acuity improved in both groupsat month 3 (from 0.06 ± 0.07 to 0.01 ± 0.03 in group 1 and 0.17 ± 0.24 to 0.09 ± 0.18 in group 2; p = 0.083and 0.183, respectively). Separately, SRF height and CVI showed a significant decrease at three months inboth groups (all p < 0.05), while a significant SRF height decrease was also noted in group 1 at one month(p = 0.038). In group 1, a significant decrease in the SFCT and CVI started at one week and one month (p =0.021 and 0.008), respectively. However, in group 2, a significant decrease in the SFCT and CVI started at onemonth and two months (p = 0.005 and 0.015), respectively. Conclusions: Acetazolamide has no effect on final functional or anatomical status at three months in eyes withCSC but does shorten the time for SRF absorption and accompanying choroidal structural changes.
Abstract
Purpose: We sought to elucidate the influence of acetazolamide on choroidal structure changes during thetreatment of central serous chorioretinopathy (CSC). Methods: This was a retrospective study of 45 eyes from 45 patients with acute CSC who were divided into anacetazolamide group (group 1, n = 20) and an observation group (group 2, n = 25). The main outcome measureswere the changes in best-corrected visual acuity, subretinal fluid (SRF) height, subfoveal choroidal thickness(SFCT), and choroidal vascularity index (CVI) at one week, one month, two months, and three months,respectively. Results: Although statistical significance was not reached, best-corrected visual acuity improved in both groupsat month 3 (from 0.06 ± 0.07 to 0.01 ± 0.03 in group 1 and 0.17 ± 0.24 to 0.09 ± 0.18 in group 2; p = 0.083and 0.183, respectively). Separately, SRF height and CVI showed a significant decrease at three months inboth groups (all p < 0.05), while a significant SRF height decrease was also noted in group 1 at one month(p = 0.038). In group 1, a significant decrease in the SFCT and CVI started at one week and one month (p =0.021 and 0.008), respectively. However, in group 2, a significant decrease in the SFCT and CVI started at onemonth and two months (p = 0.005 and 0.015), respectively. Conclusions: Acetazolamide has no effect on final functional or anatomical status at three months in eyes withCSC but does shorten the time for SRF absorption and accompanying choroidal structural changes.
참고문헌 (23)
- Wang M, "Central serous chorioretinopathy", Acta Ophthalmol, 86, pp.126~145 (2008)
- Manayath GJ, "Central serous chorioretinopathy : current update on management", Oman J Ophthalmol, 11, pp.200~206 (2018)
- Cox SN, "Treatment of chronic macular edema with acetazolamide", Arch Ophthalmol, 106, pp.1190~1195 (1988)
- Pikkel J, "Acetazolamide for central serous retinopathy", Ophthalmology, 109, pp.1723~1725 (2002)
- Imamura Y, "Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy", Retina, 29, pp.1469~1473 (2009)
- Tan KA, "Luminal and stromal areas of choroid determined by binarization method of optical coherence tomographic images", Am J Ophthalmol, 160, pp.394~ (2015)
- Agrawal R, "Choroidal vascularity index in central serous chorioretinopathy", Retina, 36, pp.1646~1651 (2016)
- Sonoda S, "Choroidal structure in normal eyes and after photodynamic therapy determined by binarization of optical coherence tomographic images", Invest Ophthalmol Vis Sci, 55, pp.3893~3899 (2014)
- Agrawal R, "Choroidal vascularity index as a measure of vascular status of the choroid : measurements in healthy eyes from a population-based study", Sci Rep, 6, pp.21090~ (2016)
- Spaide RF, "Central serous chorioretinopathy in younger and older adults", Ophthalmology, 103, pp.2070~2080 (1996)
- Guyer DR, "Digital indocyanine green videoangiography of central serous chorioretinopathy", Arch Ophthalmol, 112, pp.1057~1062 (1994)
- Spaide RF, "Indocyanine green videoangiography of older patients with central serous chorioretinopathy", Retina, 16, pp.203~213 (1996)
- Shiraki K, "Long-term follow-up of severe central serous chorioretinopathy using indocyanine green angiography", Int Ophthalmol, 21, pp.245~253 (1997)
- Iida T, "Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy", Retina, 19, pp.508~512 (1999)
- Spaide RF, "Serous detachment of the retina", Retina, 23, pp.820~846 (2003)
- Prunte C, "Choroidal capillary and venous congestion in central serous chorioretinopathy", Am J Ophthalmol, 121, pp.26~34 (1996)
- Prunte C, "Indocyanine green angiographic findings in central serous chorioretinopathy", Int Ophthalmol, 19, pp.77~82 (1995)
- Spaide RF, "Enhanced depth imaging spectral-domain optical coherence tomography", Am J Ophthalmol, 146, pp.496~500 (2008)
- Brandl C, "Choroidal thickness measurements during central serous chorioretinopathy treatment", Int Ophthalmol, 34, pp.7~13 (2014)
- Wolfensberger TJ, "The role of carbonic anhydrase inhibitors in the management of macular edema", Doc Ophthalmol, 97, pp.387~397 (1999)
- Wolfensberger TJ, "Inhibition of membrane-bound carbonic anhydrase decreases subretinal pH and volume", Doc Ophthalmol, 97, pp.261~271 (1999)
- Wolfensberger TJ, "Inhibition of membrane-bound carbonic anhydrase enhances subretinal fluid absorption and retinal adhesiveness", Graefes Arch Clin Exp Ophthalmol, 238, pp.76~80 (2000)
- Maruko I, "Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy", Retina, 31, pp.1603~1608 (2011)